Blackstone, Carlyle, KKR Eye $11 Billion Buyout

Apr 10 2013 | 10:28am ET

A trio of private equity giants are circling laboratory supplies and genetic testing company Life Technologies in what could be among the largest buyouts of the year.

The Blackstone Group, the Carlyle Group and Kohlberg Kravis Roberts, along with Singapore's sovereign wealth fund, are preparing an $11 billion bid for Life. The four were in talks late last night on terms, even after the deadline for bids passed. Should the private equity group manage to find the needed equity, Life would likely accept a bid after the deadline, according to Reuters.

The p.e. group will have to compete with a bid from Thermo Fisher Scientific, which submitted its offer yesterday.

The p.e. group as it exists is actually a merger of what could have been two competing consortia: Blackstone, Carlyle and Temasek Holdings had been working with TPG Capital, which has since dropped out, while KKR was working on a deal with other partners, who also backed out.


In Depth

Exotic Assets: Investing In Rare Violins

Jan 17 2017 | 4:43pm ET

By definition, alternative investments include exotic assets far beyond your typical...

Lifestyle

'Tis the Season: Wall Street Holiday Parties Back In Fashion

Dec 22 2016 | 9:23pm ET

Spending on Wall Street holiday parties has largely returned to pre-2008 levels...

Guest Contributor

The Trump Administration: What It Could Mean for Carried Interest

Jan 19 2017 | 5:25pm ET

The arrival of the Trump administration brings the potential for a repeal of the...

 

From the current issue of

Often seen as a passion project, or part of a philanthropic venture, rare and fine stringed instruments offer an exciting option to diversify one’s investment portfolio while providing an opportunity for an exceptional long-term investment.